Trial: 2-year study in older adults
Who: 65 healthy adults aged 60 to 81
Note: Fat-free mass rose 1.1 kg vs a 0.5 kg loss on placebo, with no gain in strength or function. Fasting glucose rose about 5 mg/dL.
Also known as: MK-677 · Ibutamoren · Ibutamoren mesylate · MK-0677 · MK677 · LUM-201 · L-163,191
Updated 26 sources
Every MK-677 (Ibutamoren) protocol on file, 16 in all, labelled by where each number came from.
Who: 65 healthy adults aged 60 to 81
Note: Fat-free mass rose 1.1 kg vs a 0.5 kg loss on placebo, with no gain in strength or function. Fasting glucose rose about 5 mg/dL.
Who: 32 healthy adults aged 64 to 81
Note: GH rose with dose. At 25 mg, 24-hour GH rose 97% and IGF-1 reached young-adult levels by 4 weeks.
Who: 8 young adults (older adults took 2 and 25 mg for 14 days)
Timing: At bedtime.
Note: 25 mg raised deep (stage IV) sleep about 50% and REM sleep more than 20% in young adults.
Who: 24 obese men aged 18 to 50
Note: IGF-1 rose about 40% and fat-free mass rose; body fat did not change, and glucose tolerance worsened.
Who: 8 healthy adults aged 24 to 39 on a restricted diet
Note: Reversed the protein (nitrogen) loss from dieting.
Who: 123 elderly hip-fracture patients
Note: Stopped early over a congestive heart failure signal in a limited number of patients.
Who: Prepubertal children with GH deficiency in Lumos Pharma trials
Note: Pediatric trials only: these are per-kg doses for prepubertal children with growth hormone deficiency, not an adult protocol. Phase 2 compared 0.8, 1.6 and 3.2 mg/kg a day with daily GH injections. The Phase 3 trial (recruiting) uses 1.6 mg/kg a day.
Timing: Before bed, to sleep through the hunger and line up with the night GH pulse.
Note: The guide starts at 10 mg for 2 weeks; most users settle at 15 to 25 mg.
Note: Ongoing use with blood work every 3 months (glucose, IGF-1, HbA1c).
Timing: Before bed, 2 or more hours after the last meal.
| When | Dose |
|---|---|
| Weeks 1 to 4 | 10 mg |
| Weeks 5 to 12 | 25 mg |
Note: The guide reassesses at week 4 and moves up to 20 to 25 mg only if 10 mg is tolerated; it says many people stay at 10 mg and tells readers not to exceed 25 mg a day.
Note: Spreads the appetite effect across the day; the daily total stays at 25 mg.
Note: Used to judge hunger and water retention before going higher.
Doses shown are what sources report, labelled by origin. Not medical advice.
Sources give no mixing notes for this product.
10 to 25 mg once a day is the usual range. Almost every adult trial used 25 mg. Many people start at 10 mg to see how the hunger and water retention go, and some stay there. Guides say going above 25 mg adds side effects without much more IGF-1.
Real but usually temporary. In the 2-year trial, more appetite was the top side effect and faded within a few months; leg swelling was mild and transient. Guides say the hunger peaks in the first 2 to 4 weeks and is gentler at 10 mg.
Nobody has proven it. Common cycles are 8 to 16 weeks on, or 12 to 16 on with 4 to 8 off. The longest trial ran 2 years straight at 25 mg and IGF-1 stayed up. Glucose is the usual reason people take breaks.
12 sources, each checked by date. Record updated Oct 24, 2026. Numbers are restated in our own words and labelled by where they came from.
Back to the full MK-677 (Ibutamoren) page for side effects, storage, stacks and legal status.